Search results
Results from the WOW.Com Content Network
Late gadolinium enhancement (LGE) and T1 mapping allow infarction and fibrosis to be identified for characterizing cardiomyopathy and assessing viability. [8] Magnetic resonance angiography may be performed with or without contrast medium and is used to assess congenital or acquired abnormalities of the coronary arteries and great vessels. [9]
The World Health Organization issued a restriction on use of several gadolinium contrast agents in November 2009 stating that "High-risk gadolinium-containing contrast agents (Optimark, Omniscan, Magnevist, Magnegita, and Gado-MRT ratiopharm) are contraindicated in patients with severe kidney problems, in patients who are scheduled for or have ...
Delayed Gadolinium-enhanced MR Imaging of Articular Cartilage: Three-dimensional T1 Mapping with Variable Flip Angles and B1 Correction; Toward Imaging Biomarkers for Glycosaminoglycans; Longitudinal Evaluation of Cartilage Composition of Matrix-Associated Autologous Chondrocyte Transplants with 3-T Delayed Gadolinium-Enhanced MRI of Cartilage
Gadoteric acid, sold under the brand name Dotarem among others, is a macrocycle-structured gadolinium-based MRI contrast agent (GBCA).It consists of the organic acid DOTA as a chelating agent, and gadolinium (Gd 3+), and is used in form of the meglumine salt (gadoterate meglumine).
An example of a ring-enhancement around a lesion in gliobastoma. In tumefactive multiple sclerosis, the ring-enhancement is open, not forming a complete ring. Tumefactive multiple sclerosis is a condition in which the central nervous system of a person has multiple demyelinating lesions with atypical characteristics for those of standard ...
They do not spread into the subcortical white matter and never show gadolinium enhancement. Over a one-year period, CLs can increase their number and size in a relevant proportion of MS patients, without spreading into the subcortical white matter or showing inflammatory features similar to those of white matter lesions.
Gadopiclenol was approved for medical use in the United States in September 2022 by the Food and Drug Administration. [2] [12]In October 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Elucirem, intended for contrast-enhanced ...
Pages in category "Gadolinium compounds" The following 25 pages are in this category, out of 25 total. This list may not reflect recent changes. G. Gadolinium acetate;